Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360703" target="_blank" >RIV/00216208:11110/17:10360703 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10360703

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.autrev.2017.04.010" target="_blank" >http://dx.doi.org/10.1016/j.autrev.2017.04.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.autrev.2017.04.010" target="_blank" >10.1016/j.autrev.2017.04.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Popis výsledku v původním jazyce

Background: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. One can therefore speculate that early initiation of highly effective immunotherapies, with an average efficacy that is superior to the typical first-line therapies, could further improve relapse and disability outcomes. However, the most common treatment strategy is to commence firstline therapies, followed by treatment escalation in patients who continue to experience on-treatment disease activity. While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider high-efficacy treatment strategies from disease onset (including induction therapy) in order to prevent irreversible disability. Objective: In this systematic review, we evaluate the effect of high-efficacy immunotherapies at different stages of MS. Methods: A systematic review of literature reporting outcomes of treatment with fingolimod, natalizumab or alemtuzumab at different stages of MS was carried out. Results and conclusions: Twelve publications reporting relevant information were included in the systematic review. The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay after the MS diagnosis. The evidence reported for disability and MRI outcomes is inconclusive. (C) 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Název v anglickém jazyce

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Popis výsledku anglicky

Background: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. One can therefore speculate that early initiation of highly effective immunotherapies, with an average efficacy that is superior to the typical first-line therapies, could further improve relapse and disability outcomes. However, the most common treatment strategy is to commence firstline therapies, followed by treatment escalation in patients who continue to experience on-treatment disease activity. While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider high-efficacy treatment strategies from disease onset (including induction therapy) in order to prevent irreversible disability. Objective: In this systematic review, we evaluate the effect of high-efficacy immunotherapies at different stages of MS. Methods: A systematic review of literature reporting outcomes of treatment with fingolimod, natalizumab or alemtuzumab at different stages of MS was carried out. Results and conclusions: Twelve publications reporting relevant information were included in the systematic review. The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay after the MS diagnosis. The evidence reported for disability and MRI outcomes is inconclusive. (C) 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Autoimmunity Reviews

ISSN

1568-9972

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

658-665

Kód UT WoS článku

000400969200012

EID výsledku v databázi Scopus

2-s2.0-85018924549